tbuckley/cabot-search huggingface dataset:
EXTH-10. THE ACTIVATION AND SENSITIZATION OF GLIOBLASTOMA CELLS VIA COLD ATMOSPHERIC PLASMA TREATMENT
Authors: Jonathan Sherman, Dayun Yan, Eda Gjika, Michael Keidar
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Treatment of glioblastoma multiforme (GBM) continues to remain a challenge using conventional treatment. Through an in vitro study we assessed the efficacy of our novel cold atmospheric plasma technology (CAP) to sensitize GBM cells to temozolomide (TMZ). METHODS The CAP jet is formed through the discharge (Pk-Pk: 5.8 kV) between a ring grounded cathode and a central anode and with He flow through a glass tube. The discharge process is driven by an AC high voltage (3.16 kV) with a frequency of 12.5 kHz. Human glioblastoma (U87MG) cells were cultured in DMEM supplemented by 1% (v/v) penicillin and streptomycin solution and 10% (v/v) FBS. CAP was delivered to U87 cells in a 96-well plate for 1 min in combination with 10 and 15 μM H2O2. The cell viability was measured by using the MTT assay. We then tested TMZ concentrations of 10 and 50 uM. Cell viability was monitored with the Cell Titer Glo 2.0. luminescent assay. All experiments were performed in triplicate and were independently repeated at least 3 times. RESULTS We identified an activation state of U87MG cells after the plasma treatment. This activation state resulted in GBM cells sensitized to reactive species identified by decreased cell viability after treatment with H2O2 as compared to the H2O2 treatment alone (p&lt; 0.005). In addition, the plasma-activated cells were sensitized to TMZ. Cells treated with CAP in combination with TMZ displayed decreased cell viability at TMZ concentrations of (10 uM) (p&lt; 0.05) and (50 uM) (p&lt; 0.005) as compared to TMZ alone. CONCLUSIONS This study demonstrates the activation phenomenon on GBM cells via direct CAP treatment. Due to this activation, the GBM cells were sensitized to both H2O2 and TMZ identified via decreased cell viability. Future work looks to assess this effect of cell activation/sensitization with chemotherapy plus radiation treatment.
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Authors: Atsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, Daisuke Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, Danbee Ha, Naoya Shigeta, Toshio Kitawaki, Yuka Maeda, Takuro Saito, Yoshinori Shinohara, Yoshihiro Kameoka, Keiko Iwaisako, Fumihiko Monma, Kohshi Ohishi, Julia Karbach, Elke Jäger, Kenichi Sawada, Naoyuki Katayama, Naoto Takahashi, Shimon Sakaguchi
Journal: The Journal of Experimental Medicine (2019)

This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK expressed in T cells. We showed that imatinib-treated CML patients in complete molecular remission (CMR) exhibited selective depletion of effector T reg (eT reg) cells and significant increase in effector/memory CD8+ T cells while non-CMR patients did not. Imatinib at CML-therapeutic concentrations indeed induced apoptosis specifically in eT reg cells and expanded tumor antigen–specific CD8+ T cells in vitro in healthy individuals and melanoma patients, and suppressed colon tumor growth in vivo in mice. Mechanistically, because of FoxP3-dependent much lower expression of LCK and ZAP-70 in T reg cells compared with other T cells, imatinib inhibition of LCK further reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptotis. Taken together, eT reg cell depletion by imatinib is instrumental in evoking effective immune responses to various cancers.
Relative Contribution of Naïve and Memory T Cells to Alloreactivity in Hematopoietic Cell Transplantation
Authors: Esteban Arrieta-Bolaños, Maryam Mohamaddokht, Thuja Meurer, Pietro Crivello, Amin T. Turki, Peter A. Horn, Dietrich W. Beelen, J.H.Frederik Falkenburg, Katharina Fleischhauer
Journal: Blood (2019)
An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma
Authors: Tim J Peterson, Neha Korde, Hani Hassoun, Sham Mailankody, Alexander M. Lesokhin, Malin Hultcrantz, Urvi A Shah, Eric L Smith, Sydney X Lu, Heather J Landau, Gunjan L. Shah, Michael Scordo, Oscar B Lahoud, Sergio A Giralt, Ola Landgren
Journal: Blood (2019)
ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN
Authors: Ahmed Idbaih, François Ducray, John DeGroot, Roger Stupp, Jacques Guyotat, Maciej S Lesniak, Adam Sonabend, Jeffrey Weinberg, Carole Desseaux, Michael Canney, Charlotte Schmitt, Alexandre Carpentier
Journal: Neuro-Oncology (2019)

Abstract The blood-brain barrier (BBB) limits penetration of systemically administered therapies to brain tumors and peritumoral tissue and may be responsible for the failure of numerous drugs in recent clinical trials for glioblastoma (GBM). Low intensity pulsed ultrasound (LIPU), with concomitant intravenous microbubble injection (DEFINITY®), can temporarily disrupt the BBB for 6–24 hours and allow for enhanced delivery of drugs to the brain. In previous clinical studies, a 1-cm ultrasound (US) device, SonoCloud-1, was implanted in a burr hole of recurrent GBM patients (n=27) and used to disrupt the BBB prior to carboplatin infusion at AUC5. This ongoing pilot phase 1/2 study (NCT03744026) aims to evaluate the safety and efficacy of transient opening of the BBB by LIPU in rGBM with the SonoCloud-9, a larger nine-emitter implantable device, designed to cover the tumor and surrounding infiltrative regions. The ultrasound device is implanted in a 6 cm x 6 cm bone flap window after tumor debulking surgery. Patients receive a 270-second sonication every month with concomitant microbubble injection to disrupt the BBB followed by carboplatin infusion at AUC4-6. Magnetic resonance imaging (MRI) is performed to verify safety and extent of BBB disruption. This study began enrollment in early 2019 and is an international, open-label, single arm, multi-site, dose-escalation and expansion trial to evaluate the safety of escalating sonication volume (“dose”) with concurrent carboplatin. The number of activated emitters in the implant (3, 6, 9) is increased using a 3 + 3 dose escalation design. Safety data of the escalation phase of the study will be presented.
NIMG-62. ATYPICAL IMAGING CHARACTERISTICS OF PRIMARY CNS LYMPHOMA AT INITIAL PRESENTATION LEADS TO FREQUENT MISDIAGNOSIS AND DELAYS IN DIAGNOSIS
Authors: Marissa Barbaro, Peter Pan, Kiran Thakur, Mary Welch
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Primary CNS lymphoma (PCNSL) has protean appearances on magnetic resonance imaging (MRI) that may lead to delays in diagnosis. METHODS We retrospectively reviewed histologically-confirmed PCNSL at Columbia University Irving Medical Center (CUIMC, 2010–2019), and characterize imaging features on pre-treatment MRI scans. RESULTS 64 patients were analyzed. 61 of 64 (95%) presented with enhancement. 35 of 64 (55%) were multiply enhancing, and 26 of 64 (41%) were singly enhancing (of which 2 were dural-based). 3 of 64 (5%) were non-enhancing. 42 of 59 (71%) had diffusion restriction. 36 of 49 (73%) lacked susceptibility. 40 of 64 (63%) were periventricular. 28 of 64 (43%) had callosal involvement. In 14 of 54 (26%), lymphoma was either not included in the differential or specifically noted less likely in radiographic report – this radiographically misdiagnosed group was significantly more likely to be either non-enhancing or non-periventricular (p=0.026). Furthermore, radiographic misdiagnosis was associated with an increased risk of a more than 14-day delay from the initial MRI to the initial invasive study, either lumbar puncture or brain biopsy (p=0.04). Presentation with a single enhancing lesion, on the other hand, was associated with significantly faster time to diagnosis – median 4.6 days (IQR 3) vs 21.6 days (IQR 4.5) from initial MRI (p=0.04). CONCLUSION In PCNSL, imaging characteristics influence outcomes. While a classic single enhancing lesion is associated with rapid diagnosis, non-enhancing and non-periventricular disease are the most likely to be misdiagnosed and require a heightened index of suspicion to avoid delays to diagnosis.
Staphylococcal Infection due to Penicillin-resistant Strains
Authors: I. Friedmann
Journal: BMJ (1948)

in hospital practice.The incidence of rheumatic fever was 'found by Coombs to be 5 girls to 4 boys ; yet the incideiice of mitral stenosis in females must be in the region of 5 to 1 male.This is due to the less active life led by girls, who are seldom permitted to be out of range of the maternal eye; they sit and knit and acquire obstructive stenosis and provide most examples of auricular fibrillation in the forties.Her brother with the same diseases escapes to the playground and, despite restrictive advice, ensures that the cusps of the mitral valve are kept well 'apart by the vigour of his exercise, thereby securing a greater volume in flow and growth of the left ventricle.At the same time he prolongs his life.Convalescent heart homes are not the nurseries for the cultivation of mitral stenosis tlhat they used to be ; nevertheless the introduction of the sedimentation rate has tended to in- crease bed rest in these cases, and mitral stenosis is actively encouraged once again.Because the sedimentation rate is increased, active endocarditis is presumed with often no justification ; it might well be tonsil, sinus, or other infection.Immobilization and fibrosis are inseparable bed-mates and are no companions for growing hearts.-Iam, etc., London, W.I.
Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia
Authors: Michael Andreeff, Jianfang Zeng, Alice Soragni, Vivian Ruvolo, Bing Z Carter, Jo Ishizawa, Jared K. Burks, David Eisenberg
Journal: Blood (2019)
Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
Authors: Michael D. Jain, Hua Zhao, Reginald Atkins, Meghan A Menges, Crystal R Pope, Rawan Faramand, Sae Bom Lee, Justin C. Boucher, Hiroshi Kotani, Christina A Bachmeier, Julio Chavez, Bijal Shah, Mohammad Hussaini, Ricardo J Gonzalez, John E Mullinax, Marco L. Davila, Frederick L. Locke
Journal: Blood (2019)
Immunosuppressive Diversity of Umbilical Cord-Derived Mesenchymal Stromal Cells
Authors: Tokiko Nagamura-Inoue, Atsuko Takahashi, Yuki Yamamoto, Akiko Hori, Yuta Miharu, Kazuo Ogami, Miwako Narita, Fumitaka Nagamura, Arinobu Tojo
Journal: Blood (2019)
Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients
Authors: Daisuke Kaji, Manabu Kusakabe, Mamiko Sakata-Yanagimoto, Yasuhito Suehara, Keiichiro Hattori, Yasunori Ota, Mitsuhiro Yuasa, Kosei Kageyama, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Atsushi Wake, Shuichi Taniguchi, Go Yamamoto, Shigeru Chiba
Journal: Blood (2019)
Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice
Authors: Nathan Eaton, Melissa M. Lee-Sundlov, Theresa A. Dlugi, Jon Wieser, Haley E. Ramsey, Martha Sola-Visner, Karin M. Hoffmeister, Hervé Falet
Journal: Blood (2019)
Weight Adjusted Urinary Creatinine Excretion Predicts Transplant Outcomes in Adult Patients with Acute Myeloid Leukemia in Complete Remission
Authors: Akihito Nagata, Noriko Doki, Yuki Otsuka, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, Kenya Toma, Yuya Kishida, Tatsuya Konishi, Yuta Yamada, Ryohei Nagata, Yuma Noguchi, Atsushi Marumo, Junichi Mukae, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Yuho Najima, Hideharu Muto, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi
Journal: Blood (2019)
Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones
Authors: Benjamin Demaree, Cyrille Delley, Cheryl Peretz, Harish Vasudevan, David Ruff, Aik Ooi, Catherine C. Smith, Adam Abate
Journal: Blood (2019)
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Authors: Julia Frede, Praveen Anand, Andrew J. Yee, Tushara Vijaykumar, Monica S. Nair, Johannes M. Waldschmidt, Sayalee V. Potdar, Jake A. Kloeber, Antonis Kokkalis, Guangwu Guo, Samantha J. Shapiro, Mason L. Mann, Robb S Friedman, Brea C. Lipe, Erica L. Campagnaro, Craig E. Cole, Elizabeth K. O'Donnell, Thomas Guerrero, Omar Nadeem, Jacob P. Laubach, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Noopur Raje, Birgit Knoechel, Jens G. Lohr
Journal: Blood (2019)
Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party
Authors: Carmen Fava, Matteo Emidio Dragani, Paola Boggione, Francesca Paoloni, Luigiana Luciano, Antonella Gozzini, Patrizia Pregno, Elisabetta Abruzzese, Carlo Gambacorti-Passerini, Giorgina Specchia, Chiara Elena, Monia Lunghi, Ester Pungolino, Franca Falzetti, Sara Galimberti, Alessandra Iurlo, Giovanni D'Arena, Giovanni Reddiconto, Claudio Fozza, Micaela Bergamaschi, Enrico Crea, Giuseppe Saglio, Giovanna Rege Cambrin
Journal: Blood (2019)
Partha Kar: Technology and the NHS—a world of false promises?
Authors: Partha Kar
Journal: BMJ (2019)

“Interoperability,” “AI,” “tech”: these phrases fly around in discussions about the NHS, but what do they mean to us? Are they just fancy buzzwords, a new fad the NHS has latched onto? Do they conjure up images of Skynet, the Terminator, and a desolate future world? Or do they suggest a much needed step change for an NHS stuck in a technological time warp? The reality, as ever, is somewhere in the middle, with emotions in the NHS ranging from unbridled enthusiasm to jaded cynicism.

One fundamental issue—and this isn’t necessarily a problem—is that the NHS can’t be seen to fail. Any failure is seen as a waste …
Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a
Authors: Judit Rejtoe, Oliver Königsbrügge, Ella Grilz, Stefanie Hofer, Johanna Gebhart, Gerhard Schuster, Clemens Feistritzer, Peter Quehenberger, Cihan Ay, Ingrid Pabinger
Journal: Blood (2019)
Increase Expression of the Genes PADI4, MPO and ELANE in the Chronic Phase of DVT Patients
Authors: Isabella Macedo Toni, Kiara Zapponi, Bidossessi Wilfried Hounkpe, Beatriz Moraes Martinelli, Silmara Aparecida De Lima Montalvão, Erich V De Paula, Joyce Maria Annichino- Bizzacchi
Journal: Blood (2019)
Red Blood Cell Deformability Demonstrated with the Oxygenscan: Exploring the Association with Hydroxyurea Treatment, Co-Inherited α-Thalassemia, and Frequency of Pain in Children with Sickle Cell Anemia
Authors: Amina Nardo-Marino, Jesper Petersen, Andreas Glenthoej, John N. Brewin, Joergen Kurtzhals, Thomas N. Williams, David C. Rees, Henrik Birgens
Journal: Blood (2019)
IMMU-12. IL13Ra2-CAR T CELLS STIMULATE ENDOGENOUS IMMUNE RESPONSES AGAINST MURINE GLIOBLASTOMAS
Authors: Darya Alizadeh, Robyn Wong, Joseph Pecoraro, Xin Yang, Stephen Forman, Christine E Brown
Journal: Neuro-Oncology (2019)

Abstract Malignant gliomas (MG) are one of the deadliest cancers with very limited therapeutic options. Chimeric antigen receptor (CAR)-T cell therapy has emerged as a powerful strategy for B-cell malignancies and may offer new opportunities to improve outcomes for patients with MGs. Our team is clinically evaluating IL13Rα2-targeted CAR-T cells for the treatment of recurrent IL13Rα2-positive MGs [NCT02208362]. While this trial is ongoing, we have previously reported that one patient with recurrent multifocal glioblastoma achieved a complete response post-IL13Rα2-CAR-T therapy despite the non-uniform expression of IL13Rα2 on the tumor. The therapeutic response against IL13Rα2-negative cells suggests CAR-T cells may stimulate endogenous immune responses. To study the interplay between CAR-T cells and host immune subsets, we have established a syngeneic immunocompetent glioma model, which recapitulates the tumor microenvironment (TME) of patients. Murine IL13Rα2-CAR-T cells mediate potent antitumor activity against IL13Rα2-engineered KR158, a highly invasive murine glioma model. Interestingly, mice “cured” from CAR-T therapy, after rechallenge, can successfully reject the tumors. Furthermore, we demonstrate comparable response rate in mice bearing gliomas with mixed antigen expression (50%IL13Rα2+/50%IL13Rα2-) vs 100% IL13Rα2+. Characterization of the TME post-CAR-T therapy indicates activation of endogenous cytotoxic CD8 T and myeloid cells, and decrease in the frequency of T regulatory cells. Further analyses reveal that tumor-associated macrophages (TAMs) may be reprogrammed during CAR-T therapy to exhibit tumoricidal activity and may promote the activation of endogenous T cells (CD4/CD8 T cells) resulting in enhanced antitumor activity. Current studies are focusing on the characterization of host immune cells to identify the mechanisms involved in induction of host immune responses mediated by CAR-T cell therapy. Our data thus strongly suggest that CAR-T therapy has the potential to reshape the glioma microenvironment creating a context permissible to elicit effective endogenous antitumor immunity.
Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction
Authors: Ersi Voskaridou, Mantzou Aimilia, Pagona Flevari, Maria Dimopoulou, Veroniki Komninaka, Konstantina Repa, Ioannis Papassotiriou
Journal: Blood (2019)
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
Authors: Reid W Merryman, Luca Castagna, Paolo Corradini, Vincent T. Ho, David A. Bond, Samantha Jaglowski, Michael A Spinner, Sally Arai, Robert Lowsky, Alex F. Herrera, Anna Guidetti, Geoffrey Shouse, Didier Blaise, Jean Marc Schiano De Colella, Talha Badar, Mehdi Hamadani, Stephen M Ansell, Yago Nieto, Chloe Spilleboudt, Tatyana A. Feldman, Lori Dahncke, Anurag K. Singh, Joseph P. McGuirk, Mohamad Mohty, Remy Dulery, Aspasia Stamatoulas Bastard, Roch Houot, Guillaume Manson, Marie-Pierre Moles, Corentin Orvain, Kamal Bouabdallah, Matthew J. Frigault, Yi-Bin Chen, Ryan C. Lynch, Stephen D. Smith, Uttam Rao, Michael T Byrne, Jason Romancik, Jonathon B. Cohen, Robin M. Joyce, Maryam Rahimian, Asad Bashey, Hatcher J. Ballard, Jakub Svoboda, Laura Giordano, Valter Torri, Beatrice Casadei, Martina Sollini, Chiara De Philippis, Massimo Magagnoli, Armando Santoro, Philippe Armand, Pier Luigi Zinzani, Carmelo Carlo-Stella
Journal: Blood (2019)
Cell therapy for pulmonary hypertension: What is the true potential of endothelial progenitor cells? Response
Authors: N Nagaya, T Horio, K Miyatake, Y Chiba, K Kangawa, M Kanda, J Hino, M Harada-Shiba, H Okumura, N Mochizuki, H Mori, M Uematsu, N Fukuyama, Y Tabata, K Nishioka, H Hara, T Asahara
Journal: Circulation (2004)
FDG PET/CT and Ultrasound Evaluation of Breast Implant–Associated Anaplastic Large Cell Lymphoma
Authors: Veska Pandika, Matthew F. Covington
Journal: Clinical Nuclear Medicine (2019)

Abstract Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a rare malignancy with isolated case reports of FDG uptake on FDG PET/CT. We present 4 cases of pathology-confirmed BIA-ALCL to illustrate varying presentations and imaging features of this disease process. Breast implant–associated anaplastic large cell lymphoma presents most commonly approximately 10 years after implantation of textured silicone or saline breast implants. Patients may present with breast enlargement, peri-implant effusion, a palpable breast or axillary mass, lymphadenopathy, breast skin erythema, or pain. Diagnosis of BIA-ALCL may be confirmed by sampling of peri-implant fluid or biopsy of peri-implant masses or regional lymph nodes.
Early Renal Disease in Children with Sickle Cell Disease from Malawi
Authors: Jonathan Brett Heimlich, Godwin Chipoka, Graham Ellis, Laila Elsherif, Emeraghi David, Portia Kamthunzi, Robert Krysiak, Yacinta Majawa, Pilirani Mafunga, Qingning Zhou, Jianwen Cai, Nigel S. Key, Satish Gopal, Kenneth I. Ataga
Journal: Blood (2016)
Evaluation of a Deep Learning–Based Automated CT Coronary Artery Calcium Scoring Algorithm
Authors: Simon S. Martin, Marly van Assen, Saikiran Rapaka, H. Todd Hudson, Andreas M. Fischer, Akos Varga-Szemes, Pooyan Sahbaee, Chris Schwemmer, Mehmet A. Gulsun, Serkan Cimen, Puneet Sharma, Thomas J. Vogl, U. Joseph Schoepf
Journal: JACC. Cardiovascular imaging (2019)
Truncated Erythropoietin Receptors Confer an In Vivo Selective Advantage in Gene-Modified Erythroid Cells Expressing Fetal Hemoglobin Due to BCL11A Interference
Authors: Naoya Uchida, Claire Drysdale, Morgan Yapundich, Jackson Gamer, Tina Nassehi, Matthew Wielgosz, Francesca Ferrara, Juan J. Haro-Mora, Selami Demirci, Aylin Bonifacino, Allen Krouse, Nathaniel S. Linde, Robert E. Donahue, Byoung Y. Ryu, John F. Tisdale
Journal: Blood (2019)
Interleukin‐22 Ameliorates Neutrophil‐Driven Nonalcoholic Steatohepatitis Through Multiple Targets
Authors: Seonghwan Hwang, Yong He, Xiaogang Xiang, Wonhyo Seo, Seung‐Jin Kim, Jing Ma, Tianyi Ren, Seol Hee Park, Zhou Zhou, Dechun Feng, George Kunos, Bin Gao
Journal: Hepatology (2019)

Background and Aims Nonalcoholic fatty liver disease encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. At present, how simple steatosis progresses to NASH remains obscure and effective pharmacological therapies are lacking. Hepatic expression of C‐X‐C motif chemokine ligand 1 (CXCL1), a key chemokine for neutrophil infiltration (a hallmark of NASH), is highly elevated in NASH patients but not in fatty livers in obese individuals or in high‐fat diet (HFD)‐fed mice. The aim of this study was to test whether overexpression of CXCL1 itself in the liver can induce NASH in HFD‐fed mice and to test the therapeutic potential of IL‐22 in this new NASH model. Approach and Results Overexpression of Cxcl1 in the liver alone promotes steatosis‐to‐NASH progression in HFD‐fed mice by inducing neutrophil infiltration, oxidative stress, and stress kinase (such as apoptosis signal‐regulating kinase 1 and p38 mitogen‐activated protein kinase) activation. Myeloid cell‐specific deletion of the neutrophil cytosolic factor 1 ( Ncf1 )/ p47 phox gene, which encodes a component of the NADPH oxidase 2 complex that mediates neutrophil oxidative burst, markedly reduced CXCL1‐induced NASH and stress kinase activation in HFD‐fed mice. Treatment with interleukin (IL)‐22, a cytokine with multiple targets, ameliorated CXCL1/HFD‐induced NASH or methionine‐choline deficient diet‐induced NASH in mice. Mechanistically, IL‐22 blocked hepatic oxidative stress and its associated stress kinases via the induction of metallothionein, one of the most potent antioxidant proteins. Moreover, although it does not target immune cells, IL‐22 treatment attenuated the inflammatory functions of hepatocyte‐derived, mitochondrial DNA‐enriched extracellular vesicles, thereby suppressing liver inflammation in NASH. Conclusions Hepatic overexpression of CXCL1 is sufficient to drive steatosis‐to‐NASH progression in HFD‐fed mice through neutrophil‐derived reactive oxygen species and activation of stress kinases, which can be reversed by IL‐22 treatment via the induction of metallothionein.